RemeGen (9995) Schedules Board Meeting on October 30, 2025 to Review Unaudited Third Quarterly Results

Bulletin Express

10/17

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited note in the announcement that they accept no liability for its contents nor for any loss arising from reliance on it.

RemeGen Co., Ltd.* (Stock Code: 9995) has announced that its board of directors will convene a meeting on Thursday, October 30, 2025. The session will consider and approve the company’s unaudited results for the nine months ended September 30, 2025, along with other matters deemed necessary. The announcement was dated October 17, 2025, from Yantai, The People’s Republic of China.

The board is chaired by Mr. Wang Weidong (also an executive director). Executive directors include Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian, and Mr. Wen Qingkai. Non-executive directors comprise Dr. Wang Liqiang and Dr. Su Xiaodi. Independent non-executive directors are Mr. Hao Xianjing, Mr. Chen Yunjin, and Mr. Huang Guobin.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1162013982"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162013982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162013982?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162013982","market":"hk","top_or_hot":-1,"title":"RemeGen (9995) Schedules Board Meeting on October 30, 2025 to Review Unaudited Third Quarterly Results","media":"Bulletin Express","content":"<p>Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited note in the announcement that they accept no liability for its contents nor for any loss arising from reliance on it.</p>\n<p>RemeGen Co., Ltd.* (Stock Code: 9995) has announced that its board of directors will convene a meeting on Thursday, October 30, 2025. The session will consider and approve the company’s unaudited results for the nine months ended September 30, 2025, along with other matters deemed necessary. The announcement was dated October 17, 2025, from Yantai, The People’s Republic of China.</p>\n<p>The board is chaired by Mr. Wang Weidong (also an executive director). Executive directors include Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian, and Mr. Wen Qingkai. Non-executive directors comprise Dr. Wang Liqiang and Dr. Su Xiaodi. Independent non-executive directors are Mr. Hao Xianjing, Mr. Chen Yunjin, and Mr. Huang Guobin.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RemeGen (9995) Schedules Board Meeting on October 30, 2025 to Review Unaudited Third Quarterly Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemeGen (9995) Schedules Board Meeting on October 30, 2025 to Review Unaudited Third Quarterly Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-17 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited note in the announcement that they accept no liability for its contents nor for any loss arising from reliance on it.</p>\n<p>RemeGen Co., Ltd.* (Stock Code: 9995) has announced that its board of directors will convene a meeting on Thursday, October 30, 2025. The session will consider and approve the company’s unaudited results for the nine months ended September 30, 2025, along with other matters deemed necessary. The announcement was dated October 17, 2025, from Yantai, The People’s Republic of China.</p>\n<p>The board is chaired by Mr. Wang Weidong (also an executive director). Executive directors include Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian, and Mr. Wen Qingkai. Non-executive directors comprise Dr. Wang Liqiang and Dr. Su Xiaodi. Independent non-executive directors are Mr. Hao Xianjing, Mr. Chen Yunjin, and Mr. Huang Guobin.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1162013982","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162013982","pubTimestamp":1760690870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited note in the announcement that they accept no liability for its contents nor for any loss arising from reliance on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"RemeGen(9995)定于2025年10月30日召开董事会，审查未经审计的第三季度业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited note in the announcement that they accept no liability for its contents nor for any loss arising from reliance on it.\nRemeGen Co., Ltd.* (Stock Code: 9995) has announced that its board of directors will convene a meeting on Thursday, October 30, 2025. The session will consider and approve the company’s unaudited results for the nine months ended September 30, 2025, along with other matters deemed necessary. The announcement was dated October 17, 2025, from Yantai, The People’s Republic of China.\nThe board is chaired by Mr. Wang Weidong (also an executive director). Executive directors include Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian, and Mr. Wen Qingkai. Non-executive directors comprise Dr. Wang Liqiang and Dr. Su Xiaodi. Independent non-executive directors are Mr. Hao Xianjing, Mr. Chen Yunjin, and Mr. Huang Guobin.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}